was reflected in the lack of effect of thesecompounds on the parameters of the microsomal mixed-function oxidase complex measured. These results would thus support the use of the measurement of D-glucuronic acid metabolites in urine as a n assessment of hepatic xenobiotic-metabolizing-enzyme activities in the rat.
Resistance to anticancer drugs has been increasingly recognized to depend not only on heritable resistance in tumour clones derived from the wild-type, but also on host-and tumour-cell-derived factors that alter behaviour of the wild-type tumour cell so that it masquerades as resistant.
Selective cell kill in each patient also depends on the behaviour of the applied anticancer drug, which is often appreciably different from patient to patient. In the case of a cytotoxic pteridine, methotrexate, our gene replication model of a major class of methotrexate-resistant mutants (McIntyre et d., 1975 ) also provided a rational basis for the clinical importance of estimating both extracellular drug concentration and the degree of saturation of the specific intracellular target protein, dihydrofolate reductase, which had been made apparent previously (Newbold & Harding, 1971) .
The inter-patient variation in drug handling indicates that good therapeutic control could be best achieved by monitoring methotrexate in each patient. If this approach is expanded to each of the principal anticancer drugs, then an active treatment centre is faced with a required throughput of several hundred drug assays per week for the different drugs. In addition some therapeutic programmes involve use of tumour-cell synchrony techniques as a means of investigating the enhancement of cell kill and of minimizing non-tuniour cell toxicity. For biochemically-reversible anticancer drugs such as methotrexate, proper investigation demands results from drug assays on a cell-cycle time scale.
Speed of assay must also be associated with sensitivity and specificity. Most anticancer drugs function at relatively low concentration, in the range 0 . 0 6~~ (5-fluorouracil) to O.OOO1 ~U M (vincristine) calculated from effective clinical doses and the volume of distribution. High dose regimes may yield transient concentrations in the mM range. Techniques must distinguish also between parent drug and non-toxic metabolites at these concentrations and between the drug and its congeners and naturally occurring derivatives of similar structure.
Specific and sensitive radioimmunoassays often have the disadvantage of being slow and of having to use an isotopicendpoint. Depending on the method, days can be required to obtain an answer, though in our investigations of methotrexate radioimmunoassays results could be produced in hours.
We therefore decided to develop a programme of enzyme-multiplied immunoassays (Rubenstein eta/., 1972) for anticancer drugs. By using methotrexate as a model we have been able to devise the required rapid assay, studying antibody specification to components of the drug, ligand coupling and factors affecting the terminal enzyme label.
Analogue drugs such as methotrexate are structurally very similar to a wide range of naturally occurring folate coenzymes. Some of these can not only bypass action of the drug, but also could be recognized by antibodies directed to common structures in the drug and its natural congeners. In the case of methotrexate and folate derivatives, the principal difference is in the pteridine where a 4-amino group replaces the natural 4-hydroxy group, a 10-methyl group being added to the drug to decrease intestinal toxicity. The 2,4-diamino structure is thought to reorient the molecule at its biological binding site to prevent reduction of the condensed pyrazine ring (Newbold & Harding, 1971) . At the outset we were concerned that antibody production might not be sufficiently specific that only the 4-amino group is specified on the pteridine terminus. Accordingly we undertook a survey of antigens prepared by coupling both the carboxy (Harding, 1971) and pteridine termini (Harding et a/., 1973) to a wide range of backbone macromolecules. By using this approach for studying antibody specification, our conclusions are broadly similar to the radioimmunoassay findings of Aherne et a/. (1977) . In addition we found that the predominant naturally occurring plasma folate, 5-methyltetrahydrofolate and intracellular derivatives, 10-formyltetrahydrofolate and 5,1O-methylenetetrahydrofolate, were not cross, reactant to methotrexate with rabbit antibodies we had specified for the pteridine of methotrexate.
Antigenicity of the pteridine-linked and carboxy-linked derivatives favoured the latter, which fortuitously had the advantage of a simpler synthesis. Nevertheless some rabbits gave a lesser response than others, leading to an investigation of whether monoclonal studied by using immobilized methotrexate (Newbold & Harding, 1971 ) and chaotropic elution with and without counter-substrates. We conclude that provided the response to immunization proceeds well, enrichment may not be necessary on the grounds of sensitivity or specificity.
The choice of terminal enzyme label is important when high sample throughput is being considered in a clinical context. There may be an intrinsic blank in an enzyme immunoassay derived from a similar enzyme in the plasma, urine or tissue sample. This is especially important with some tumours and in cytotoxic therapy where hepatocellular damage may temporarily yield abnormal amounts of catalytically active circulating enzymes. Carboxy-coupling of methotrexate (Harding, 1971 ; Newbold &Harding, 1971) to glutamate dehydrogenase, malate dehydrogenase and glucose 6-phosphate dehydrogenase was examined. On the question of clinically derived blank values the last enzyme is notable in having a large amount of clinical data available and in showing substratedependent activation in some preparations (Sigma (32256) . Ligand coupling at pH5.6 proceeds well, it being important to balance conditions to maintain catalytically active monomer enzyme yet produce a molar incorporation of up to 5mol of methotrexate per mol of enzyme. The balance between the molar incorporation ratio and cross-linking effects studied by acrylamide-gel electrophoresis confirms that best control of linking conditions is obtained at the specified pH and on ice. Substrate-analogue studies of glucose 6-phosphate dehydrogenase indicated that sensitivity of the final assay was related to the presence of enzyme substrates during ligand coupling, presumably by influencing the site of insertion of methotrexate molecules on the enzyme. Catalytic activation of the ligand-enzyme complex depends on the molar-incorporation ratio, polyacrylamide-gel studies confirming that an unwarranted loss of activity can occur by cross linking of complexes and that these do not seem to activate in the same way as monomer enzyme.
We conclude that by the carboxy-coupling route optimum conjugation between methotrexate and glucose 6-phosphate dehydrogenase provides an assay with little or no non-specific background from clinical samples, which is highly specific for methotrexate, adequately sensitive, tailored for high clinical throughput by using a spectrophotometer and can yield results in minutes. For high throughput, experience indicates that glucose 6-phosphate dehydrogenase may have advantages over other enzyme labels (Scharpe ef al., 1976) . This requires establishing for high-volume throughput assays of anticancer drugs where tissue lysis may yield increased circulating non-specific enzyme activity. Nevertheless, this rapid enzyme immunoassay of methotrexate has the additional advantage of stability over our previous enzyme assay that used an 02-and phosphate-labile folate substrate (Newbold & Harding, 1971) .
